Unknown

Dataset Information

0

Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel.


ABSTRACT:

Background

Pancreatico-biliary adenocarcinomas (PBA) have a poor prognosis. Diagnosis is usually achieved by imaging and/or endoscopy with confirmatory cytology. Cytological interpretation can be difficult especially in the setting of chronic pancreatitis/cholangitis. Immunohistochemistry (IHC) biomarkers could act as an adjunct to cytology to improve the diagnosis. Thus, we performed a meta-analysis and selected KOC, S100P, mesothelin and MUC1 for further validation in PBA resection specimens.

Methods

Tissue microarrays containing tumour and normal cores in a ratio of 3:2, from 99 surgically resected PBA patients, were used for IHC. IHC was performed on an automated platform using antibodies against KOC, S100P, mesothelin and MUC1. Tissue cores were scored for staining intensity and proportion of tissue stained using a Histoscore method (range, 0-300). Sensitivity and specificity for individual biomarkers, as well as biomarker panels, were determined with different cut-offs for positivity and compared by summary receiver operating characteristic (ROC) curve.

Results

The expression of all four biomarkers was high in PBA versus normal ducts, with a mean Histoscore of 150 vs. 0.4 for KOC, 165 vs. 0.3 for S100P, 115 vs. 0.5 for mesothelin and 200 vs. 14 for MUC1 (p?ConclusionA biomarker panel of KOC, S100P and mesothelin with at least 2 biomarkers positive was found to be an optimum panel with both 10% and 20% cut-offs in resection specimens from patients with PBA.

SUBMITTER: Ali A 

PROVIDER: S-EPMC4112611 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel.

Ali Asif A   Brown Victoria V   Denley Simon S   Jamieson Nigel B NB   Morton Jennifer P JP   Nixon Colin C   Graham Janet S JS   Sansom Owen J OJ   Carter C Ross CR   McKay Colin J CJ   Duthie Fraser R FR   Oien Karin A KA  

BMC clinical pathology 20140723


<h4>Background</h4>Pancreatico-biliary adenocarcinomas (PBA) have a poor prognosis. Diagnosis is usually achieved by imaging and/or endoscopy with confirmatory cytology. Cytological interpretation can be difficult especially in the setting of chronic pancreatitis/cholangitis. Immunohistochemistry (IHC) biomarkers could act as an adjunct to cytology to improve the diagnosis. Thus, we performed a meta-analysis and selected KOC, S100P, mesothelin and MUC1 for further validation in PBA resection spe  ...[more]

Similar Datasets

| S-EPMC6033365 | biostudies-literature
| S-EPMC8192334 | biostudies-literature
| S-EPMC5862596 | biostudies-literature
| S-EPMC6343270 | biostudies-literature
| S-EPMC10670525 | biostudies-literature
| S-EPMC9184404 | biostudies-literature
| S-EPMC5477371 | biostudies-literature
2021-08-13 | GSE181961 | GEO
| S-EPMC7882677 | biostudies-literature
| 2113133 | ecrin-mdr-crc